/ /

Fred Gebhart
The author is a correspondent for Urology Times, a sister publication.
Precision medicine coming to glaucoma via specific pathways
Characterizing the genetic elements linked to different types of glaucoma, such as in the Primary Open-Angle African American Glaucoma Genetics study, could help clinicians develop more precise and effective treatments.
Head to head: Balanced phaco tip more efficient than Kelman tip
Researchers share findings from a comparison of relative efficiency and chatter of two phaco tips with identical optimal settings.
Growing number of devices set to transform glaucoma treatment
Minimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
New technologies on horizon to redefine drug delivery
Glaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
Shire utilizing biotech approach to meet unmet ophthalmic needs
Shire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.
Glaucoma, dry eye drugs center of pharmaceutical opportunities
The pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
B + L places focus on innovation in pharma, surgical, vision care
Bausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Aerie’s focus on therapies that address cause of vision loss
Aerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
Teleglaucoma redefining role in future of blindness prevention
'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.

Poll

View Results